Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

Pfizer (NYSE:PFE) announced Friday that a late-stage clinical trial for inclacumab, its experimental therapy for the blood ...

For Q1 2018 (ended on March 31), Global Blood Therapeutics posted $41.6M ($0.87 per share) net losses compared to $23.3M ($0.60 per share) declines (for the same period a year prior).

A Comparison Of Global Blood Therapeutics' GBT440 And bluebird bio's LentiGlobin Apr. 07, 2017 4:14 PM ET Pfizer Inc. (PFE) Stock AES, BLUE, SCD PFE 11 Comments Emerging Equities 1.35K Follower s ...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 ...

* Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016 Source text for Eikon: Further ...

* Global blood therapeutics reports recent business progress and provides second quarter 2016 financial results * Q2 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S Source text for Eikon ...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and ...